Goldman Sachs just upgraded this ASX 200 tech share

This could be the tech share to buy right now according to the broker.

| More on:
A man holding a cup of coffee puts his thumb up and smiles while at laptop.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Pro Medicus Limited (ASX: PME) share price has been on fire in 2023.

Since the start of the year, the ASX 200 tech share has risen approximately 23%.

Where next for this ASX 200 tech share?

The good news for investors is that analysts at Goldman Sachs don't believe it is too late to buy Pro Medicus shares.

According to a note, the broker has upgraded the company's shares to a buy rating with a $76.00 price target.

Based on the current Pro Medicus share price of $67.94, this implies a potential upside of 12% for investors over the next 12 months.

What did the broker say?

The broker has been impressed with the health imaging technology company's recent contract wins and feels there could be more coming. It highlights that "Visage 7 looks set for a robust period of transaction revenue as PME on-boards several large accounts."

This is underpinned by the "growing importance of a radiology IT system that can materially improve efficiency" and the "competitive advantage of PME's offerings."

Goldman acknowledges that this ASX 200 tech share is not cheap on paper. However, it believes it deserves to trade at a premium. This is due to its highly profitable business, strong growth potential, and robust balance sheet.

On our estimates, PME currently trades on 63x NTM EV/EBITDA (noting we are +13-14% above EBITDA consensus in FY24/25E after incorporating the latest contract wins). Whilst it doesn't look cheap on near-term multiples: i) the business is highly profitable (>50% net margins); ii) cash flows are recurrent/long-dated in nature (5/7-year contracts); and iii) the balance sheet looks robust ($80m net cash).

Our new estimates imply a +22% EBITDA CAGR (FY23-26E), a 'multiple to growth' ratio of 2.9x, which we view as undemanding vs. ASX Healthcare on 2.2x. We view PME as the clear incumbent technology leader in a growth market with low-risk market share upside from <10% today, and the optionality to broaden/deepen into a platform solution for adjacent/complementary offerings. We upgrade to Buy.

All in all, Goldman appears to believe this could be one tech share to buy and hold.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Technology Shares

group of traders cheering at stock market
Technology Shares

What drove a 10% surge in ASX 200 tech shares last week?

The ASX 200 roared to a 2-month high on Friday, with tech shares leading the 11 market sectors last week.

Read more »

A man slumps crankily over his morning coffee as it pours with rain outside.
Technology Shares

Why is the Block share price crashing 33%?

This payment giant's shares are being hammered today. But why?

Read more »

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company
Technology Shares

These ASX 200 tech stocks could rise 20% to 35%

Goldman Sachs is tipping these shares to rise strongly from current levels.

Read more »

A corporate team or board stands together and looks out the window.
Technology Shares

WiseTech shares charge higher on $3.5b acquisition news

This tech stock is ending the week positively. But why?

Read more »

A man leans forward over his phone in his hands with a satisfied smirk on his face although he has just learned something pleasing or received some satisfying news.
Technology Shares

3 reasons to buy this $25 billion ASX 200 tech stock today

A top expert forecasts more outperformance from this fast-growing ASX 200 tech stock.

Read more »

Lines of codes and graphs in the background with woman looking at laptop trying to understand the data.
Technology Shares

Why is the Brainchip share price crashing 9% today?

The semiconductor company is being sold off on Tuesday. But why?

Read more »

A man with a wide, eager smile on his face holds up three fingers.
Technology Shares

3 reasons this sold-off ASX 200 share is primed for a big rebound

A leading expert believes this ASX 200 share is well placed to outperform.

Read more »

a man surrounded by huge piles of paper looks through a magnifying glass at his computer screen.
Technology Shares

I did some research on Siteminder — Here's what you should know

The big questions I'm monitoring for answers.

Read more »